Therapeutic Response

CD20 + status confers therapeutic sensitivity to Corticosteroid in combination with Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, and Vincristine in patients with Non-Hodgkin Lymphoma.

Statements

Source and description

MabThera (rituximab) [product information]. EMA. The European Medicines Agency (EMA) has authorized rituximab in combination with chemotherapy for the treatment of pediatric patients (aged >= 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL) / Burkitt leukemia (mature B-cell acute leukemia) (BAL) or Burkitt-like lymphoma (BLL). This indication is based on a multicenter, open-label, randomized study of Lymphome Malin B (LMB) chemotherapy (corticosteroids, vincristine, cyclophosphamide, high-dose methotrexate, cytarabine, doxorubicin, etoposide and triple drug [methotrexate/cytarabine/ corticosteroid] intrathecal therapy) alone or in combination with rituximab.